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Identity 
Other names: ARHGAP7, FLJ21120, HP, STARD12, 
p122-RhoGAP 
HGNC (Hugo): DLC1 
Location: 8p22 
DNA/RNA 
Note 
GeneLoc location for GC08M012985: 
Start: 12940872 bp from pter, 
End: 13372395 bp from pter, 
Size: 475895 bases, 
Orientation: minus strand. 
Description 
DLC1 was first isolated from human hepatocellular 
carcinoma (HCC) by PCR-based subtractive 
hybridization method in 1998 (Yuan et al., 1998). It 
maps to human chromosome 8p21.3-22, a region 
recurrently deleted in HCC and other solid tumors. 
Several isoforms of DLC1 have been found, namely 
DLC1alpha (isoform 2), DLC1beta (isoform 1) and 
DLC1gamma (isoform 3). DLC1alpha, DLC1beta and 
DLC1gamma contain 15 exons, 19 exons and 6 exons 
respectively. 
Transcription 
Transcript size: 
DLC1alpha: 6044 bp (NM_006094), 
 
Genomic organization of human DLC1. (A) Schematic diagram illustrating chromosomal location of human DLC1 at 8p22. Arrow 
underneath the gene symbol indicates the orientation of transcription. LOC340357, hypothetical transcript; C8orf79/C8orf48, 
chromosome 8 open reading frame 79/48; LOC100131565, pseudo eIF4-like; SGCZ, Sacroglycan, zeta. (B) Genomic organization of 
human DLC1 locus. Coding (filled boxes) and non-coding (horizontal lines) regions are shown. Arrow represents the position of the 
transcriptional start site. 
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DLC1beta: 7445 bp (NM_182643), 
DLC1gamma: 1975 bp (NM_024767). 
Among the three DLC1 isoforms, DLC1alpha 
represents the predominant isoform. It has a unique 5' 
untranslated region and a transcript size of 6044 bp. 
DLC1beta has the longest transcript size of 7445 bp. It 
contains a total of 19 exons including exons 2 to 14 of 
DLC1alpha and another 5 exons upstream of the 
transcriptional start site of DLC1alpha. DLC1gamma is 
the shortest isoform with a transcript size of 1975 bp. It 
shares the first 5 exons with DLC1gamma and has a 
unique exon 6. 
CpG islands have been reported to be found in -387 to 
+502 and +554 to +765 of DLC1alpha promoter. In this 
region, 11 SP1 and 4 GCF transcription factor binding 
sites (-162 to +67) have also been documented (Yuan et 
al., 2003). Genomic deletions and promoter 
hypermethylation are responsible for the 
underexpression of DLC1 not only in HCC but in 
various cancer cells and tissues (Wong et al., 2003; 
Durkin et al., 2007a). DLC1beta and gamma share the 
same promoter region and are formed by alternative 
splicing at the 3' end. One potential AP-1 site has been 
reported to be localized at -134 position in DLC1beta 
and gamma promoter region. The absence of CpG 
island in DLC1beta and gamma promoter region 
suggests that their expressions are less likely to be 
transcriptionally regulated by epigenetic alterations. 
Protein 
Note 
Protein size: 
DLC1alpha: 1091 amino acids; 122 kDa, 
DLC1beta: 1528 amino acids, 
DLC1gamma: 498 amino acids. 
Description 
DLC1alpha and beta are structurally similar containing 
SAM, RhoGAP and START domains. DLC1alpha 
encodes a 1091-amino acid protein with a predicted 
molecular weight of 122 kDa. Comparing with 
DLC1alpha, DLC1beta possesses a longer N-terminal 
region. It encodes a protein of 1529 amino acids. 
DLC1gamma is the smallest isoform of DLC1 with 
only 498 amino acids and has no functional domains. It 
shares the N-terminal region with DLC1beta isoform.  
Functional domains: 
 
SAM (Sterile Alpha Motif) 
Interpro: IPR001660; SAM 
Pfam: PF07647; SAM_2 
PROSITE: PS50105; SAM_DOMAIN 
RhoGAP (RhoGTPase Activating Protein) 
Interpro: IPR000198; RhoGAP 
Pfam: PF00620; RhoGAP 
PROSITE: PS50238; RHOGAP 
SMART: SM00324; RhoGAP 
START (STeroidogenic Acute Regulatory related lipid 
Transfer) 
Interpro: IPR002913; START_lipid_bd 
Pfam: PF01852; START 
PROSITE: PS50848; START 
SMART: SM00234; START 
Expression 
Northern blot analysis showed that DLC1 is 
ubiquitously expressed in normal human tissues with 
high abundance in lung and ovary (Yuan et al., 1998). 
Quantitative PCR analysis showed that DLC1alpha is 
the dominant isoform in all human tissues examined, 
except in heart tissue whereas DLC1beta is the most 
abundant isoform in the heart. Among all the normal 
tissues examined, DLC1alpha is relatively abundant in 
the lung and ovary. Besides, it is moderately expressed 
in the thyroid, spleen, intestine and kidney, and least 
expressed in the adrenal gland, liver and pancreas. 
DLC1gamma is rarely detectable in tissues. Although 
DLC1 was first identified as a putative tumor 
suppressor gene in HCC, accumulating studies have 
supported that DLC1 is involved in various human 
cancers. Frequent underexpression of DLC1 has been 
detected in a wide range of tumor tissues and cancer 
cell lines. Both genomic deletions and epigenetic 
silencing are responsible for the underexpression of 
DLC1. 
Localisation 
Subcellular localization of ectopically expressed DLC1 
was first reported to be present in the cytoplasm of 
HCC cell lines, Focus and 7703K (Zhou et al., 2003). 
DLC1 was later reported to be colocalized with 
vinculin when expressed in cells (Yam et al., 2006). 
DLC1 has been reported to interact with tensin proteins 
at focal adhesions. Focal adhesion localization is 
crucial to the tumor suppression activity of DLC1 (Liao 
et al., 2007; Qian et al., 2007; Chan et al., 2009). 
 
Schematic representation of DLC1 protein. DLC1 is a multiple-domain protein including sterile alpha motif (SAM), Rho GTPase 
activating protein (RhoGAP) and StAR-related lipid transfer (START) domains. 
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It is also intriguing to note the presence of nuclear 
localization signal (NLS) and nuclear export sequences 
(NES) in DLC1. It is reported that the presence of a 
basic residues rich motif in DLC1 resembling the NLS 
is responsible for the nucleocytoplasmic shuttling of 
DLC1 (Yuan et al., 2007). It has been shown that 
activated protein kinase C (PKC) and protein kinase D 
(PKD) stimulate the association between DLC1 and 14-
3-3 proteins. The enhanced association blocks DLC1 
nucleocytoplasmic shuttling and inhibits the RhoGAP 
activity of DLC1 (Scholz et al., 2009). 
Function 
Since the identification of DLC1 in 1998, accumulating 
studies have well characterized DLC1 as a bona fide 
tumor suppressor not only in HCC, but in diverse 
human cancers (Liao and Lo, 2008). DLC1 encodes a 
protein containing three major functional domains, 
namely, sterile alpha motif (SAM) at the N-terminus, 
and RhoGAP and steroidogenic acute regulatory 
(StAR)-related lipid transfer (START) domains at the 
C-terminus. RhoGAP activity has been demonstrated to 
be critical for the biological activities of DLC1. It 
possesses selective activity towards RhoA, RhoB and 
RhoC and less towards CDC42 but not Rac1 (Wong et 
al., 2003; Healy et al., 2008). Abrogation of 
Rho/ROCK-mediated cytoskeleton reorganization by 
DLC1 has been shown to be RhoGAP dependent 
(Wong et al., 2008). DLC1 RhoGAP defective mutant 
failed to inhibit stress fiber formation in HCC cells 
(Wong et al., 2005). 
The tumor and metastasis suppressive effects of DLC1 
have been well characterized by ectopic expression of 
DLC1 in various cancer cell lines. Extensive studies 
have shown that the RhoGAP activity is crucial to the 
biological activities of DLC1. Introduction of DLC1 
into cancer cell lines has been shown to suppress cell 
proliferation (Ng et al., 2000), inhibit cell migration 
and invasion (Wong et al., 2005; Qian et al., 2007), and 
induce apoptosis (Zhou et al., 2004). Moreover, 
restoration of DLC1 expression has been shown to 
inhibit metastasis of cancer cells in mouse model 
(Goodison et al., 2005). Functional data about the loss 
of DLC1 in HCC tumorigenesis was first demonstrated 
in a mouse model using a liver-specific, short-hairpin 
RNA-mediated DLC1 knockdown approach (Xue at al., 
2008). In p53 null; c-myc-transduced mouse 
hepatoblasts, RNAi knockdown of DLC1 could 
promote in vivo tumorigenicity of cells. Apart from 
RhoGAP activity, proper focal adhesion localization 
and interaction with tensin proteins have been 
demonstrated to play important roles in the biological 
activities of DLC1 (Yam et al., 2006; Liao et al., 2007; 
Qian et al., 2007; Chan et al., 2009). Other proteins 
including caveolin-1 (Yam et al., 2006), p120RasGAP 
(Yang et al., 2009) and 14-3-3 (Scholz et al., 2009) 
protein have also been identified as interacting partners 
of DLC1 with functional implications. Using knockout 
mouse model, DLC1 has been shown to be crucial to 
the early embryonic development of mouse (Durkin et 
al., 2005). DLC1
-/-
 embryos are embryonic lethal while 
DLC1
+/-
 mouse is phenotypically normal. Mouse 
embryonic fibroblasts isolated from DLC1 deficient 
mice displayed altered cytoskeletal organization and 
focal adhesions.  
Regulation 
DLC1 is widely expressed in normal human tissues, but 
it is frequently underexpressed in HCC and other 
cancers. Heterozygous deletion and promoter 
hypermethylation of DLC1 are commonly found in 
about 30-50% of cases in various human cancers (Yuan 
et al., 2003a). Although DLC1 expression and activity 
have been well documented to be regulated at the 
transcriptional level, recent studies about the regulation 
of RhoGAP activity, interacting potentials and 
subcellular localization of DLC1 have pointed to an 
essential regulatory role by the central region of DLC1. 
In the central focal adhesion targeting region of DLC1, 
somatic mutations of DLC1 have been first detected in 
human prostate cancers (Liao et al., 2008). These 
mutations impaired the RhoGAP activity of DLC1. 
Crucial residues in the central region have also been 
shown to be responsible for proper focal adhesion 
localization and interacting with tensin proteins (Chan 
et al., 2009; Liao et al., 2007). Mutation at these crucial 
residues caused DLC1 to lose its focal adhesion 
localization and tumor suppressive activity. More 
importantly, the central region has been subjected to 
post-translational modifications. Scholz et al. have 
suggested that PKD-mediated DLC1 phosphorylation 
stimulates the association between DLC1 and 14-3-3 
proteins. Enhanced association blocks DLC1 
nucleocytoplasmic shuttling and inhibits the RhoGAP 
activity of DLC1 (Scholz et al., 2009). Moreover, 
identification of rat homolog of DLC1, p122RhoGAP 
as the substrate of Akt has provided insights into other 
potential regulatory pathways of DLC1 (Hers et al., 
2006). However, the functional significance Akt 
phosphorylation in p122RhoGAP and its relevance in 
human DLC1 have not been investigated. 
Homology 
DLC family members (DLC1, DLC2 and DLC3) are 
structurally conserved with high sequence homology 
(Durkin et al., 2007b). DLC2 localizes at human 
chromosome 13q12.3 while DLC3 maps to human 
chromosome Xq13. DLC1 shares 58% and 44% amino 
acid identities with DLC2 and DLC3 respectively. 
Mutations 
Note 
Somatic mutations of DLC1 have been reported to be 
rarely found in HCC, colorectal and ovarian cancers 
(Wilson et al., 2000; Park et al., 2003). Until recently, 
DLC1 mutations have been reported in colorectal and 
prostate cancers (Liao et al., 2008). Mutational analysis 
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of human genomic and cDNA has been performed in 
nucleotide sequence encoding the focal adhesion 
targeting region (201-500 amino acids) of DLC1. 
Somatic 
(Reference sequence: NM_006094) 
Colorectal cancer (N=37) 
1243 G->T (S308I) - (1/37) 2.7% 
1279 G->T (S320I) - (1/37) 2.7% 
1333 AC->TA (Y338L) - (1/37) 2.7% 
1336 T->A (L339*) - (1/37) 2.7% 
Prostate cancer (N=28) 
1189 C->T (P290L) - (2/28) 7.1% 
1222 C->A (T301K) - (1/28) 3.6% 
1243 G->T (S308I) - (3/28) 10.7% 
1249 C->A (S310*) - (1/28) 3.6% 
The nonsense mutations (S310* and L339*) resulted in 
truncated DLC1 proteins with the loss of intact focal 
adhesion targeting region, RhoGAP and START 
domains. These truncated proteins are nonfunctional. 
Colony formation assay revealed that both T301K and 
S308I mutants displayed significant reduction in 
growth suppression activities. In addition, RhoGAP 
activity was downregulated in the two mutants as well. 
Implicated in 
Hepatocellular carcinoma 
Note 
DLC1 was isolated from human HCC by PCR-based 
subtractive hybridization method in 1998 (Yuan et al., 
1998). It was mapped to chromosome 8p21.3-22, a 
region suspected to harbor tumor suppressor genes and 
recurrently deleted in HCC and other solid tumors. 
DLC1 gene is widely expressed in normal human 
tissues, but it is frequently underexpressed in primary 
HCCs ranging from 20-68% and in half of the HCC 
cell lines examined (Ng et al., 2000; Wong et al., 2003; 
Ko et al., 2010). It has been reported that epigenetic 
silencing is responsible for DLC1 underexpression. 
Hypermethylation of DLC1 promoter has been detected 
in both HCC tissues and cell lines. Apart from 
promoter hypermethylation, homozygous deletion of 
DLC1 gene was detected. Frequent allelic loss of 
DLC1 locus was observed in primary HCCs and HCC 
cell lines (Ng et al., 2000; Wong et al., 2003). 
However, somatic mutation of DLC1 gene was not 
detected (Park et al., 2003). Introduction of DLC1 into 
HCC cell lines suppressed growth, migration, invasion 
and in vivo tumorigenicity (Ng et al., 2000; Zhou et al., 
2004; Wong et al., 2005). DLC1 also induced apoptosis 
when ectopically expressed in HCC cell lines (Zhou et 
al., 2004). Expression of DLC1 in HCC cells 
negatively regulated Rho/ROCK/MLC2 pathway and 
induced disassembly of actin fibers and focal adhesions 
(Wong et al., 2008). In another study, DLC1 has been 
shown to downregulate expressions of osteopontin and 
matrix metalloproteinase-9 in HCC cells (Zhou et al., 
2008). 
Breast cancer 
Note 
Reduced or absence of DLC1 mRNA level was 
detected in up to 76% of breast cancer tissues and 70% 
of breast cancer cell lines (Plaumann et al., 2003; Yuan 
et al., 2003b; Ullmannova et al., 2006; Seng et al., 
2007). Genomic deletion was detected in 40% of 
primary breast tumors (Yuan et al., 2003b) and 
promoter hypermethylation was detected in breast 
cancer cell lines (Yuan et al., 2003a). Transfection of 
DLC1 into breast cancer cells led to significant 
inhibition of cell growth, reduction of colony formation 
and suppression of in vivo tumorigenicity (Yuan et al., 
2003b). Combined knockdown of PTEN and DLC1 
expressions enhanced breast cancer cell migration 
(Heering et al., 2009). In addition, restoration of DLC1 
in metastatic breast cancer cells resulted in the reduced 
migration and invasion potentials in vitro and inhibited 
metastasis in vivo (Goodison et al., 2005). 
Lung cancer 
Note 
Using a cancer profiling array containing tumor and 
normal tissue samples derived from cancer patients, a 
study revealed that DLC1 mRNA level was 
downregulated in 90% of lung cancer tissues 
(Ullmannova et al., 2006). Yuan et al. also reported that 
DLC1 mRNA expression was decreased or absent in 
95% of human primary non-small cell lung carcinoma 
(NSCLC) and 58% of NSCLC cell lines (Yuan et al., 
2004). Silencing of DLC1 has been attributed to 
aberrant methylation of DLC1 promoter. When DLC1 
was expressed in NSCLC cell line in which DLC1 was 
not expressed, cell proliferation, colony formation and 
in vivo tumorigenicity were greatly reduced. In 
addition, DLC1 has been shown to suppress anchorage 
independent growth and invasion of NSCLC cells 
(Healy et al., 2008). 
Ovarian cancer 
Note 
DLC1 mRNA level has been reported to be suppressed 
in 79% of ovarian cancer tissues (Ullmannova et al., 
2006). DLC1 has also been reported as one of the genes 
to be upregulated by progesterone in ovarian cancer 
cell line (Syed et al., 2005). Introduction of DLC1 in 
ovarian cancer cells resulted in growth inhibition and 
enhancement of caspase-3 activity. In addition, DLC1 
also abrogated soft agar colony formation and invasion 
of ovarian cancer cells. 
Kidney cancer 
Note 
DLC1 underexpression was detected in 75% of kidney 
tumor tissues (Ullmannova et al., 2006). In another 
study, it is reported that high levels of DLC1 mRNA 
and protein expression were observed in 90% of normal 
renal tissues. DLC1 expression level in primary tumors  
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with metastases was significantly lower that that in 
cases without metastases. DLC1 underexpression was 
significantly correlated with the advanced histological 
grade and stage (Zhang et al., 2009a). Overexpression 
of DLC1 in renal cell carcinoma cells resulted in 
dramatic growth inhibition and ability to form tumor in 
nude mice. The inhibitory activity was associated with 
the induction of apoptosis and cell cycle arrest (Zhang 
et al., 2009b). Conversely, suppression of DLC1 
expression was associated with higher proliferative 
activity. Besides, reintroduction of DLC1 inhibited cell 
migration and induced dephosphorylation of focal 
adhesion kinase. 
Colon cancer 
Note 
Downregulation of DLC1 mRNA expression was 
detected in 43% of colon cancer tissues (Ullmannova et 
al., 2006) and 70% of colon cancer cell lines examined 
(Yuan et al., 2003a). Mutational analysis of genomic 
DNA from normal and colon cancer patients revealed 
that no mutation was found in normal samples while 4 
mutations were detected in cancer samples (Liao et al., 
2008). Reintroduction of DLC1 expression in HT29 
cells significantly inhibited proliferation and migration 
potentials of cells. Flow cytometry revealed that DLC1 
induced apoptosis and cell cycle arrest in cells (Wu et 
al., 2009). Using a complementary approach, silencing 
of DLC1 in LoVo colon cancer cells resulted in 
enhanced cell growth and migration (Jin et al., 2008). 
Gastric cancer 
Note 
Ullmannova et al. reported that DLC1 mRNA was 
downregulated in 41% of gastric cancer tissues 
(Ullmannova et al., 2006). In another study, Kim et al. 
reported that DLC1 mRNA expression was lost in 7 out 
of 9 human gastric cancer cell lines (Kim et al., 2003). 
In 5 of these DLC1 nonexpressing gastric cancer cell 
lines, DLC1 promoter was methylated. DLC1 mRNA 
expression could be restored by the addition of 5-aza-
2'-deoxycytidine (5-Aza-dC). In addition, the study 
also revealed that 30% of primary gastric cancers 
showed methylation of DLC1 CpG island. 
Prostate cancer 
Note 
Underexpression or loss of DLC1 mRNA was detected 
in prostate carcinomas and cell lines and benign 
prostatic hyperplasias (Yuan et al., 2003a; Guan et al., 
2006). Absence of DLC1 protein was also detected in 
prostate carcinomas and benign prostatic hyperplasias. 
Promoter methylation and genomic deletion were 
identified in prostate carcinomas. DLC1 methylation 
was significantly correlated with the age of prostate 
cancer patients and with prostate-specific antigen in 
benign prostatic hyperplasia patients. In 3 prostate 
cancer cell lines with low DLC1 expression, addition of 
cells with inhibitors of DNA methyltransferase or 
histone deacetylase induced reexpression of DLC1 
level. In addition, several missense and nonsense 
mutations within the central focal adhesion targeting 
region of DLC1 were detected in cDNAs of prostate 
cancer patients (Liao et al., 2008). Adenovirus-
mediated expression of DLC1 in prostate cancer cells 
inhibited cell proliferation, anchorage-independent 
growth, invasion in vitro and tumorigenicity in nude 
mice. In addition, DLC1 also induced cell cycle arrest. 
Rho activation and actin stress fiber formation were 
also suppressed by DLC1 (Guan et al., 2008). 
Nasopharyngeal carcinoma (NPC) 
Note 
Silencing of DLC1 was detected in 91% of 
nasopharyngeal carcinoma cell lines examined (Seng et 
al., 2007). Although no genomic deletion of DLC1 was 
detected in NPC, hemizygous deletion was observed in 
some NPC cell lines. DLC1 promoter was frequently 
methylated in NPC cancer cell lines and 89% of 
primary tumors. In 2 NPC cell lines, 5-Aza-dC 
treatment caused reexpression of DLC1 level and 
decrease in methylated alleles of DLC1. 
Esophageal carcinoma 
Note 
DLC1 underexpression was detected in 40% of 
esophageal carcinoma cell lines examined (Seng et al., 
2007). In the same study, analysis of DLC1 promoter 
region revealed that 51% of esophageal carcinomas 
were methylated and none of the normal esophageal 
tissues displayed methylation. Ectopic expression of 
DLC1 in esophageal carcinoma cells showed 
significant inhibition in colony formation. 
Cervical cancer 
Note 
About 63% of cervical cancer cell lines examined 
showed underexpression of DLC1 (Seng et al., 2007). 
DLC1 promoter was methylated in 87% of primary 
cervical carcinomas. 
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